Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/ofid/ofab336 http://scihub22266oqcxt.onion/10.1093/ofid/ofab336 34307731!8294673!34307731     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Open+Forum+Infect+Dis 2021 ; 8 (7): ofab336 Nephropedia Template TP {{tp|p=34307731|t=2021. Reduced Mortality With Ondansetron Use in SARS-CoV-2-Infected Inpatients |pdf=|usr=}}{{34307731}} gab.com Text Reduced Mortality With Ondansetron Use in SARS-CoV-2-Infected Inpatients JO: Open Forum Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=34307731 #FOAvip BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has led to a surge in clinical trials evaluating investigational and approved drugs. Retrospective analysis of drugs taken by COVID-19 inpatients provides key information on drugs associated with better or worse outcomes. METHODS: We conducted a retrospective cohort study of 10 741 patients testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 3 days of admission to compare risk of 30-day all-cause mortality in patients receiving ondansetron using multivariate Cox proportional hazard models. All-cause mortality, length of hospital stay, adverse events such as ischemic cerebral infarction, and subsequent positive COVID-19 tests were measured. RESULTS: Administration of >/=8 mg of ondansetron within 48 hours of admission was correlated with an adjusted hazard ratio for 30-day all-cause mortality of 0.55 (95% CI, 0.42-0.70; P < .001) and 0.52 (95% CI, 0.31-0.87; P = .012) for all and intensive care unit-admitted patients, respectively. Decreased lengths of stay (9.2 vs 11.6; P < .001), frequencies of subsequent positive SARS-CoV-2 tests (53.6% vs 75.0%; P = .01), and long-term risks of ischemic cerebral ischemia (3.2% vs 6.1%; P < .001) were also noted. CONCLUSIONS: If confirmed by prospective clinical trials, our results suggest that ondansetron, a safe, widely available drug, could be used to decrease morbidity and mortality in at-risk populations. Twit Text FOAVip Reduced Mortality With Ondansetron Use in SARS-CoV-2-Infected Inpatients ????Open Forum Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=34307731 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34307731 #FOAvip English Wikipedia <ref>{{Cite pmid|34307731}}</ref> Reduced Mortality With Ondansetron Use in SARS-CoV-2-Infected Inpatients #MMPMID34307731 Bayat V; Ryono R; Phelps S; Geis E; Sedghi F; Etminani P; Holodniy M Open Forum Infect Dis 2021[Jul]; 8 (7): ofab336 PMID34307731show ga BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has led to a surge in clinical trials evaluating investigational and approved drugs. Retrospective analysis of drugs taken by COVID-19 inpatients provides key information on drugs associated with better or worse outcomes. METHODS: We conducted a retrospective cohort study of 10 741 patients testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 3 days of admission to compare risk of 30-day all-cause mortality in patients receiving ondansetron using multivariate Cox proportional hazard models. All-cause mortality, length of hospital stay, adverse events such as ischemic cerebral infarction, and subsequent positive COVID-19 tests were measured. RESULTS: Administration of >/=8 mg of ondansetron within 48 hours of admission was correlated with an adjusted hazard ratio for 30-day all-cause mortality of 0.55 (95% CI, 0.42-0.70; P < .001) and 0.52 (95% CI, 0.31-0.87; P = .012) for all and intensive care unit-admitted patients, respectively. Decreased lengths of stay (9.2 vs 11.6; P < .001), frequencies of subsequent positive SARS-CoV-2 tests (53.6% vs 75.0%; P = .01), and long-term risks of ischemic cerebral ischemia (3.2% vs 6.1%; P < .001) were also noted. CONCLUSIONS: If confirmed by prospective clinical trials, our results suggest that ondansetron, a safe, widely available drug, could be used to decrease morbidity and mortality in at-risk populations. äReduced Mortality With Ondansetron Use in SARS-CoV-2-Infected Inpatien(epmc).pdf DeepDyve Pubget Overpricing